Pyxis Oncology, Inc. announced dosing of the first subject in the Phase 1 trial of PYX-106. PYX-106 is a fully human immunotherapy antibody candidate that is designed to block the activity of Siglec-15, an immune suppressor expressed across a broad range of tumors. The Company also announced that the second dose level has been initiated in the ongoing Phase 1 trial of PYX-201, a novel antibody-drug conjugate (ADC) product candidate licensed from Pfizer targeting extradomain-B (EDB) of fibronectin, a non-internalizing antigen that is an integral component of the extracellular matrix in tumors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.15 USD | -0.48% | -4.38% | +130.56% |
05-14 | Earnings Flash (PYXS) PYXIS ONCOLOGY Posts Q1 Revenue $16.1M | MT |
05-14 | Pyxis Oncology, Inc. Appoints Stephen Worsley as its Senior Vice President | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+130.56% | 244M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- PYXS Stock
- News Pyxis Oncology, Inc.
- Pyxis Oncology, Inc. Advances Pyx-106 and PYX-201 Clinical Programs